article thumbnail

AI, big data and real world evidence – the challenges and opportunities

pharmaphorum

Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations in medicine. Data collected like this is also acceptable to regulators, pointed out Medrano, meaning that it can be used during the clinical development process. About BREATHE.

Big Data 118
article thumbnail

Big data – charting a new path to drug discovery and development

Drug Discovery World

For example, Sanofi, Pfizer, Gilead, Novartis, BMS, Genentech, and Bayer have all announced significant alliances to integrate these big data technologies into drug discovery operations. Given the state of the field, much of the FDA guidance to date has been around the regulation of AI in medical devices.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inside the European mass shift to data-driven health solutions

Pharmaceutical Technology

Countries like Estonia and Finland have taken on a completely digitised approach to their health services , integrating EHR data to efficiently prescribe medications and improve treatment strategies. Darwin is part of a package of projects and initiatives to transform to data-driven medicines regulation.”.

Big Data 278
article thumbnail

EMA unveils first projects as data partners join DARWIN EU project

pharmaphorum

Two years ago, the EMA proposed a set of recommendations to unlock the potential of big data for public health, headlined by the creation of a platform to access and analyse healthcare data from across the bloc. With the first data partners on board, the regulator can now move ahead with the start of its first studies.

article thumbnail

EMA urges “human-centric approach” to AI in drug discovery

Drug Discovery World

The EMA has published a draft reflection paper outlining the current thinking on the use of artificial intelligence (AI) to support the safe and effective development, regulation and use of medicines. The use of AI is rapidly developing in society and as regulators we see more and more applications in the field of medicines. “The

Drugs 40
article thumbnail

Deep Learning-based Interoperability: Advanced Neural Networks Mimicking the Human Brain

Roots Analysis

In addition to the advances in processing power of computing machines and the development of smarter algorithms, big data is considered to be one of the key drivers of growth in this segment. Big data holds great promise in terms of its potential applications in the healthcare industry as mentioned below.

article thumbnail

Integrated evidence generation 2.0: A strategy for every stakeholder

pharmaphorum

These groundbreaking discoveries ushered in a new age of precision and personalized medicine, leading to innovations in novel targeted proteins, cell and gene therapies, and medical devices, which are often accompanied by bespoke diagnostic and testing criteria. The evidence‑generation process has become far more challenging.